Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells

26 Sept 2017

Abstract excerpt

// Meike Kaehler 1 , Johanna Ruemenapp 1 , Daniel Gonnermann 2 , Inga Nagel 1 , Oliver Bruhn 1 , Sierk Haenisch 1 , Ole Ammerpohl 3 , Daniela Wesch 2 , Ingolf Cascorbi 1 and Henrike Bruckmueller 1 1 Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany 2 Institute of Immunology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA and Nucleic Acid Chemistry
Share to Drug Transport and Resistance Mechanisms
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29190894
DOI: 10.18632/oncotarget.21272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cellsPMID 29190894Read ↗

MicroRNA profiling in K-562 cells under imatinib treatmentSemantic proximity Read ↗

miR-495-3p Sensitizes BCR::ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cellsSemantic proximity Read ↗

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.Semantic proximity Read ↗

Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562Semantic proximity Read ↗

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistanceSemantic proximity Read ↗

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1Semantic proximity Read ↗

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutationsSemantic proximity Read ↗

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.Semantic proximity Read ↗

Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.Semantic proximity Read ↗

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR–ABL proteinSemantic proximity Read ↗

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2Semantic proximity Read ↗

MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.